Filing Details
- Accession Number:
- 0001127602-20-032211
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-22 16:11:05
- Reporting Period:
- 2020-12-21
- Accepted Time:
- 2020-12-22 16:11:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1682852 | Moderna Inc. | MRNA | Biological Products, (No Disgnostic Substances) (2836) | 813467528 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1690927 | Zvi Tal Zaks | C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-21 | 10,000 | $20.93 | 10,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-12-21 | 2,339 | $12.21 | 12,339 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-12-21 | 4,790 | $19.15 | 17,129 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-21 | 601 | $138.10 | 16,528 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 3,035 | $140.11 | 13,493 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 2,876 | $140.83 | 10,617 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 1,020 | $142.03 | 9,597 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 3,415 | $143.25 | 6,182 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 3,300 | $144.28 | 2,882 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 2,382 | $145.23 | 500 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-21 | 500 | $146.19 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-21 | 10,000 | $0.00 | 10,000 | $20.93 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-21 | 2,339 | $0.00 | 2,339 | $12.21 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-21 | 4,790 | $0.00 | 4,790 | $19.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 191,998 | 2020-03-08 | 2029-03-08 | No | 4 | M | Direct |
| 194,952 | 2027-10-03 | No | 4 | M | Direct | |
| 0 | 2026-08-10 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.93 to $138.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.40 to $140.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.41 to $141.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.57 to $142.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.70 to $143.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.71 to $144.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.77 to $145.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.10 to $146.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
- This option is fully vested and exercisable.
Billionaire Hedge Funds
